# Evaluation of Endothelial Dysfunction Using the Flow Mediated Dilation Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies

Study · id `cardio:ct-nct06347029` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06347029](<https://clinicaltrials.gov/study/NCT06347029>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06347029

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06347029. Non-randomized; no masking; primary purpose basic science. Start 2023-10-17 (actual); primary completion 2024-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose basic science
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06347029, source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)
- Started: 2023-10-17 (actual) (ClinicalTrials.gov record NCT06347029, source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)
- Primary completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT06347029, source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)
- Completion: 2024-12-31 (anticipated) (ClinicalTrials.gov record NCT06347029, source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)
- Countries: Belgium (ClinicalTrials.gov record NCT06347029, source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06347029-2024-04-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Endothelial Dysfunction Using the "Flow Mediated Dilation" Test in a Population of Chronic Renal Failure Patients at Different Stages, and Evaluation of the Role of Antiphospholipid Antibodies
- Condition: Chronic Renal Failure
- Intervention (Procedure): Urine sampling
- Intervention (Procedure): Blood sampling
- Intervention (Device): Flow mediated dilatation test
- Lead sponsor: Brugmann University Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 1659c14d3aec41a7ce2097afc9fe58f70ee0f1559b5237b0444495f30823e53b
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
